Anzeige
Mehr »
Mittwoch, 27.08.2025 - Börsentäglich über 12.000 News
Patentschutz bis in die 2040er - Biotech-Geheimtipp vor möglichem Fast-Track-Durchbruch in den USA!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A404NJ | ISIN: US08771Y4026 | Ticker-Symbol:
NASDAQ
26.08.25 | 21:34
0,392 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SRX HEALTH SOLUTIONS INC Chart 1 Jahr
5-Tage-Chart
SRX HEALTH SOLUTIONS INC 5-Tage-Chart
GlobeNewswire (Europe)
96 Leser
Artikel bewerten:
(0)

SRx Health Solutions, Inc.: SRx Health Solutions Announces Receipt of Late Filing Notification Letter from NYSE American

TAMPA, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company"), a leading global health and wellness company, today announced that on August 20, 2025, it received an official notice from NYSE Regulation indicating that the Company is not in compliance with the continued listing standards of NYSE American LLC (the "Exchange") as set forth in Section 1007 of the NYSE American Company Guide. The notice was issued because the Company did not timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the "Delinquent Report") with the Securities and Exchange Commission (the "SEC") by the required due date of August 19, 2025.

During the six-month period from the date of the Filing Delinquency (the "Initial Cure Period"), the Exchange will monitor the Issuer and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Issuer, until the Filing Delinquency is cured. If the Issuer fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in the Exchange's sole discretion, allow the Issuer's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Issuer's specific circumstances.

The Company is working diligently with its auditors and advisors to complete the Delinquent Report as soon as practicable. The Company is currently anticipating filing the Delinquent Report on or before the cure period deadline.

This notice does not immediately affect the listing or trading of the Company's common stock on the Exchange. The Company intends to regain compliance with the Exchange's listing standards. While there can be no assurance that it will regain compliance with all applicable Exchange listing standards, the Company is confident it will comply with all listing standards.

About SRx Health Solutions, Inc.
SRx Health Solutions Inc. is an integrated Canadian healthcare services provider that operates within the specialty healthcare industry. The SRx network extends across all ten Canadian provinces, making it one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in the country. SRx combines years of industry knowledge, technology, and patient-centric focus to create strategies and solutions that consistently exceed client expectations and drive critical patient care initiatives aimed to improve the wellness of Canadians.?For more information on SRx Health Solutions Inc., please visit www.srxhealth.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company's risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
T: 212-896-1254
Valter@KCSA.com


© 2025 GlobeNewswire (Europe)
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.